Highlights 2012 - Gilde Healthcare

December 20, 2012

Season’s Greetings and best wishes for a healthy and prosperous New Year in 2013 from Gilde Healthcare Partners.

We look back on an eventful year of successes and a lot of hard work. Click below for our 2012 highlights.

More news

Gilde Healthcare portfolio company Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics to expand bioanalysis capabilities in clinical drug development

Gilde Healthcare portfolio company Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, has today announced that it has acquired Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland. The move...

May 19, 2022

Gilde Healthcare company Amphista Therapeutics enters a up to $1.0 billion strategic collaboration with Merck

Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39 million ($44 million) in combined upfront and R&D funding...

May 4, 2022

Gilde Healthcare company Amphista Therapeutics enters a up to $1.25 billion strategic collaboration with Bristol Myers Squibb

Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics Collaboration includes an upfront payment of $30 million, the potential for up to...

May 4, 2022